RUTHERFORD, N.J. and STOCKHOLM, April 03, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced an agreement with OneTwo Analytics AB, a leading healthtech company specializing in AI-driven analytics for diabetes data including continuous glucose monitoring (CGM), diabetes technology stack development, and clinical study data analysis. Through this collaboration, Glucotrack will leverage next-generation artificial intelligence and machine learning-based analytics to evaluate clinical study data from its Continuous Blood Glucose Monitor (CBGM)

Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption (IDE) approval for continuous blood glucose monitoring (CBGM) technology from FDA expected in Q4 2025 Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2024. "2024 was transf

RUTHERFORD, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that safety and performance data from its first-in-human trial of its long-term continuous blood glucose monitoring (CBGM) system will be presented at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes (ATTD). ATTD is an important global conference focused on technological innovations in diabetes care. The conference will be held in Amsterdam, the Netherlands, taking place March 19 – 22, 2025. "We are pleased to be showcasing th

RUTHERFORD, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Guillermo Umpierrez, MD, CDCES, FACE, MACP, has been named as Glucotrack's new Medical Advisory Board member, effective immediately. "With his invaluable experience in diabetes care and his dedication to improving the lives of people with diabetes, Dr. Umpierrez brings exceptional clinical and research expertise that will be instrumental as we advance our novel Continuous Blood Glucose Monitoring (CBGM) technology through clinical development," said Paul V.

Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a "best efforts" public offering of approximately 2.6 million shares of common stock. The offering price of each share of common stock is $1.15, The gross proceeds of the public offering are expected to be approximately $3.0 million before deducting agent placement fees and offering expenses. The closing of the public offering is expected to occur on or about February 5, 2025, subject to the satisfaction of customary closing conditions. Dawson James

RUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the successful completion of its first in human clinical study, marking a significant milestone in continuous glucose monitoring. This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations often seen with traditional continuous glucose monitors that measure glucose levels in interstitial fluid.

RUTHERFORD, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect a 1-for-20 reverse stock split (the "Reverse Stock Split") of its issued and outstanding common stock par value $0.001 per share (the "Common Stock"), effective with the opening of trading on Tuesday, February 4, 2025. Glucotrack's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "GCTK". The new CUSIP number for the Common Stock following the Reverse Stock Split will

RUTHERFORD, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that Peter C. Wulff has been named Chief Financial Officer, effective immediately. Mr. Wulff has over 35 years of financial management experience in both public and privately held companies in the emerging growth life sciences sector. He has a strong track record of successfully raising capital through a variety of mechanisms including public and private equity offerings, debt financing, and strategic business transactions. Mr

RUTHERFORD, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has received ISO 13485:2016 certification from the British Standards Institute (BSI). "This ISO certification is a major step in our journey toward delivering high-quality products," said Paul V. Goode, PhD, President and Chief Executive Officer. "Meeting these rigorous global standards for design and manufacturing demonstrates our dedication to quality and regulatory excellence as we continue to achieve clinical and d

RUTHERFORD, N.J., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Ted Williams has been named Vice President of Regulatory Affairs, effective immediately. Mr. Williams has nearly 25 years of experience and a proven track record of successful management of Regulatory Affairs and Quality Assurance for highly complex Class III medical devices including active, long term implantable continuous glucose monitors ("CGM"), drug/device combination products, in-dwelling catheter based endovascula

1-for-5 reverse stock split to become effective as of the opening of trading onMay 20, 2024 Rutherford, NJ, May 15, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect a 1-for-5 reverse stock split (the "Reverse Stock Split") of its issued and outstanding common stock (the "Common Stock"), effective with the opening of trading on Monday, May 20, 2024. Glucotrack's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "GCTK". The new CUSIP number

4 - GlucoTrack, Inc. (0001506983) (Issuer)

RUTHERFORD, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Guillermo Umpierrez, MD, CDCES, FACE, MACP, has been named as Glucotrack's new Medical Advisory Board member, effective immediately. "With his invaluable experience in diabetes care and his dedication to improving the lives of people with diabetes, Dr. Umpierrez brings exceptional clinical and research expertise that will be instrumental as we advance our novel Continuous Blood Glucose Monitoring (CBGM) technology through clinical development," said Paul V.

RUTHERFORD, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that Peter C. Wulff has been named Chief Financial Officer, effective immediately. Mr. Wulff has over 35 years of financial management experience in both public and privately held companies in the emerging growth life sciences sector. He has a strong track record of successfully raising capital through a variety of mechanisms including public and private equity offerings, debt financing, and strategic business transactions. Mr

RUTHERFORD, N.J., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Ted Williams has been named Vice President of Regulatory Affairs, effective immediately. Mr. Williams has nearly 25 years of experience and a proven track record of successful management of Regulatory Affairs and Quality Assurance for highly complex Class III medical devices including active, long term implantable continuous glucose monitors ("CGM"), drug/device combination products, in-dwelling catheter based endovascula

Biotech veteran joins Glucotrack's Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes Rutherford, NJ, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the appointment of John Ballantyne, PhD to its Board of Directors, effective immediately. "We are pleased to welcome John, who has been a long-standing supporter of the Company, to our Board of Directors," said Paul Goode, PhD, President and CEO of Glucotrack. "An entrepreneur himself, John

Glucotrack expands leadership team with clinical trial expertise for the continuous blood glucose monitor for people with diabetes Rutherford, NJ, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Sandie Martha has joined the Company as Vice President of Clinical Operations. "Sandie brings a wealth of knowledge and expertise to the team in leading clinical trials for both glucose monitoring and cardiology." said Paul Goode, PhD, President and CEO of Glucotrack. "The breadth and depth of

Diabetes industry veteran joins Glucotrack's Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes Rutherford, NJ, June 20, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has appointed Andy Balo to its Board of Directors, effective immediately. Mr. Balo brings decades of regulatory, clinical and quality experience in the medical technology industry. In 2002 he joined Dexcom as part of the original executive team where he remained for the next

Rutherford, NJ, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes announced today that Luis Malavé has been elected as Chairman of its Board of Directors, effective immediately. "I can think of no better person to lead our Board during this exciting and pivotal time for Glucotrack," said Andrew Sycoff, member of the Board of Directors. "With a deep commitment to the mission and values of the organization, Luis will be an invaluable strategic leader for the continued growth of the company." Mr. Malavé brings m

Rutherford, NJ, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has appointed Erin Carter to its Board of Directors and as Chair of its Audit Committee, effective immediately. Ms. Carter brings 30 years of executive level finance experience in the medical device industry. From 2012 until March of 2023, she held various senior roles with Medtronic, most recently serving as Chief Financial Officer and Vice President of Finance for their $9B Neuroscience division. In addition, during her tenure at Medtronic s

8-K - Glucotrack, Inc. (0001506983) (Filer)

8-K - Glucotrack, Inc. (0001506983) (Filer)

10-K - Glucotrack, Inc. (0001506983) (Filer)

8-K - Glucotrack, Inc. (0001506983) (Filer)

8-K - Glucotrack, Inc. (0001506983) (Filer)

8-K - Glucotrack, Inc. (0001506983) (Filer)

8-K - Glucotrack, Inc. (0001506983) (Filer)

8-K - Glucotrack, Inc. (0001506983) (Filer)

424B5 - Glucotrack, Inc. (0001506983) (Filer)

8-K - Glucotrack, Inc. (0001506983) (Filer)

4 - Glucotrack, Inc. (0001506983) (Issuer)

4 - Glucotrack, Inc. (0001506983) (Issuer)

4 - Glucotrack, Inc. (0001506983) (Issuer)

4 - Glucotrack, Inc. (0001506983) (Issuer)

4 - Glucotrack, Inc. (0001506983) (Issuer)

4 - Glucotrack, Inc. (0001506983) (Issuer)

4 - Glucotrack, Inc. (0001506983) (Issuer)

4 - Glucotrack, Inc. (0001506983) (Issuer)

3 - Glucotrack, Inc. (0001506983) (Issuer)

3 - Glucotrack, Inc. (0001506983) (Issuer)

SC 13G - Glucotrack, Inc. (0001506983) (Subject)

SC 13G - GlucoTrack, Inc. (0001506983) (Subject)